Introduction {#Sec1}
============

Iron influences glucose metabolism, and the link between iron metabolism and diabetes is well established \[[@CR1], [@CR2]\]. The relationship is bidirectional: iron affects glucose metabolism, and glucose metabolism interferes with several iron metabolic pathways. Whereas excessive iron seems to be involved in the pathogenesis of diabetes, iron deficiency has been linked with obesity and insulin resistance. However, the crosstalk between iron and energy metabolism as well as pathophysiological processes such as inflammation, peripheral ischemia, and hypoxia is still not fully understood \[[@CR3]\].

Although the HbA1c value is well established as a biomarker for the diagnosis of diabetes and for monitoring the treatment of diabetes, its reliability, especially under conditions of an altered iron homeostasis, has been challenged. HbA1c levels appear to be affected by iron status, as several studies have demonstrated increased values under conditions of iron depletion and iron deficiency anemia (IDA) in both type 1 diabetic and nondiabetic populations \[[@CR4]--[@CR7]\]. On the other hand, iron substitution therapy results in a significant drop in HbA1c values \[[@CR5]--[@CR7]\]. There is evidence that iron-associated elevations and reductions in HbA1c do not properly reflect glycemic status, resulting in a spuriously exaggerated number of people that are diagnosed with pre-diabetes and diabetes and overtreatment when HbA1c is used as the primary indicator for glycemic control \[[@CR8]--[@CR10]\].

The hypothesis to be tested in the CLEVER trial is that infusion of ferric carboxymaltose (FCM) in patients with type 2 diabetes (T2DM) and iron deficiency (ID) significantly reduces HbA1c, as has already been shown for other populations, e.g., nondiabetic people and patients with type 1 diabetes. The reliability of HbA1c as an indicator for glycemic control will be assessed by the concomitant determination of fasting blood glucose and fructosamine. Moreover, the treatment of ID and metabolic status improvement are expected to have an impact on the overall quality of life, which will be evaluated as a secondary endpoint.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

The CLEVER trial is designed as a multicenter, randomized, single-blind, proof-of-concept study. Men and women with T2DM and ID are randomized 1:1 to treatment with either FCM or placebo (0.9% NaCl solution) administered as an intravenous drip infusion over 30 min. The aim of the study is to investigate a systematic influence of ID on HbA1c. Participants will also be monitored for the occurrence of treatment-emergent adverse events and overall health status. After confirming eligibility at the screening visit (V1a), participants will enter the treatment phase, consisting of three visits. At visit 1b, baseline data for iron and metabolic status and quality of life will be recorded, and the first dose of the study medication will be administered. FCM (Ferinject^®^, Vifor Pharma Deutschland GmbH) will be dosed at 500 or 1000 mg, depending on the individual body weight and hemoglobin level (Fig. [1](#Fig1){ref-type="fig"}). This will be followed by an observation period of 30 min to monitor the tolerability of the infusion. Iron status will be assessed based on the following laboratory parameters: ferritin, transferrin, transferrin saturation (TSAT), soluble transferrin receptor (sTFR), serum iron, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, % hypochromic cells, reticulocyte hemoglobin content, and hepcidin. HbA1c, fasting blood glucose, and fructosamine as well as the insulin dosage used will serve as markers to assess the metabolic status. Overall health status and quality of life (QoL) will be evaluated by the Euro-QoL (EQ5D) questionnaire. In accordance with the summary of product characteristics (SmPC) and the study protocol, participants will receive a second dose of study medication at visit 2a, which is scheduled for 4 weeks after the first dose. In cases where iron deficiency persists, a third dose will be administered approximately 5 days after the second dosing (visit 2b). Finally, primary and secondary outcome parameters will be assessed at the end-of-study visit scheduled for 8 weeks after the application of the final dose of study medication. The visit schedule, including study-related actions/measures, is shown in Table [1](#Tab1){ref-type="table"}.Fig. 1CLEVER study design. ^\#^Defined as HbA1c ≥ 48 mmol/mol (6.5%) and \< 69 mmol/mol (8.5%). ^\#\#^Defined as serum ferritin \< 150 ng/mL or transferrin saturation \< 25% if hemoglobin \< 14 g/dL or serum ferritin \< 100 ng/mL or transferrin saturation \< 20% if hemoglobin ≥ 14 g/dL and ≤ 15 g/dL. \*Control parameter: ferritin and transferrin saturation. \*\*If still iron deficient at V2a \[serum ferritin \< 150 ng/mL or transferrin saturation \< 25%\], an additional dose of 500 mg ferric carboxymaltose is given at V2b, otherwise it is not Table 1Visit schedule and study-related actions/measuresVisit1a1b2a(2b)\*3Week 0\
Day 0\
ScreeningWeek 1\
Day 7 ±\
5 days\
BaselineWeek 5\
± 14 daysWeek 5\
± 14 days\
+ 5 daysWeek 13\
± 14 days\
End of studyInformed consent✓Inclusion/exclusion criteria✓Demographic data✓Height, weight, BMI, waist circumference✓Anamnesis/medical history✓Urine pregnancy test✓Concomitant medication✓✓✓(✓)✓Randomization✓Vital signs (blood pressure, pulse, body temperature)✓✓✓(✓)✓Laboratory✓✓✓Study drug administration✓✓(✓)Adverse event and serious adverse event✓✓(✓)✓Documentation of used insulin and blood glucose✓✓✓Euro-QoL (EQ5D) questionnaire✓✓✓\* If still iron deficient \[serum ferritin \< 150 ng/mL or ferritin saturation \< 25%\], an additional visit (visit 2b) for administration of 500 mg ferric carboxymaltose is necessary, otherwise it is not

This trial is registered under the US National Institutes of Health ClinicalTrials.gov identifier NCT01513369. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Study Population {#Sec4}
----------------

Men and women 18 years or older and diagnosed with T2DM as well as ID (defined as serum ferritin \< 150 ng/mL or transferrin saturation \< 25% if hemoglobin \< 14 g/dL; or serum ferritin \< 100 ng/mL or transferrin saturation \< 20% if hemoglobin ≥ 14 g/dL and ≤ 15 g/dL) are eligible for inclusion in the CLEVER trial. HbA1c values between 48 and 69 mmol/mol (6.5% and 8.5%) were defined for inclusion in the study based on data from El-Agouza et al. \[[@CR7]\], who showed that HbA1c values of nondiabetic people treated with iron were reduced from 6.15% ± 0.62% to 5.25% ± 0.45%. Consequently, it was hypothesized that people with T2DM will demonstrate a similar response. A detailed list of inclusion and exclusion criteria is given in Table [2](#Tab2){ref-type="table"}.Table 2Key inclusion and exclusion criteriaKey inclusion criteriaMen and women older than 18 years\
Diagnosis of type 2 diabetes and iron deficiency defined as follows:\
 HbA1c ≥ 48 mmol/mol (6.5%) and \< 69 mmol/mol (8.5%)\
 Serum ferritin \< 150 ng/mL or transferrin saturation \< 25% if hemoglobin \< 14 g/dL\
 Serum ferritin \< 100 ng/mL or transferrin saturation \< 20% if hemoglobin ≥ 14 g/dL and ≤ 15 g/dLKey exclusion criteriaContinuous subcutaneous insulin infusion\
Thalassemia\
Hemoglobin \> 15 g/dL (≥ 9.31 mmol/L)\
C-reactive protein \> 15 mg/L\
Change in HbA1c of more than ± 0.3% within the last 3 months\
Hypersensitivity to the active substance, to Ferinject, or to any of its excipients\
Known serious hypersensitivity to other parenteral iron products\
History of acquired iron overload\
History of erythropoietin-stimulating agent, IV or high-dose oral iron therapy or blood transfusion \< 12 weeks prior to randomization\
Body weight ≤ 40 kg\
Chronic or active liver disease\
Vitamin B12 and/or serum folate deficiency\
Current malignancy under treatment\
Renal function GFR \< 30 mL/min/1.73 m^2^\
Significant major cardiovascular disease ongoing or in the past 3 months\
Polyneuropathy without ischemia\
Pregnant or nursing (lactating) women\
Any person not willing to use adequate contraceptive precautions during the study and for up to 5 days after the last scheduled dose of study medication

The protocol will be conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines and approved by each center's institutional ethics review board. Informed consent for inclusion in the study will be obtained from all patients.

Study Objectives {#Sec5}
----------------

The primary aim of the study is to confirm that HbA1c levels are reduced after iron repletion therapy in people with ID and T2DM, as has already been reported for different populations such as healthy subjects, pregnant women, or patients with type 1 diabetes \[[@CR5], [@CR6], [@CR11]\]. Moreover, the interrelationships of iron treatment and the subsequent reduction in HbA1c with selected parameters of overall health status and glucose metabolism will be assessed in more detail. For this purpose, changes in primary and secondary endpoints between baseline and 12 weeks after the start of intravenous iron repletion therapy will be evaluated. A full list of primary and secondary endpoints is presented in Table [3](#Tab3){ref-type="table"}.Table 3Study endpointsPrimary endpointChange in HbA1c from baseline to the end of the studySecondary endpointsChange in iron status from baseline to the end of the study as measured by hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, % hypochromic cells, reticulocyte hemoglobin content, ferritin, transferrin, transferrin saturation (TSAT), soluble transferrin receptor (sTFR), serum iron, hepcidin\
Change in metabolic status from baseline to the end of the study as measured by fasting blood glucose and fructosamine\
Change in insulin dosage used per application from baseline to the end of the study\
Reliability of HbA1c measurements\
Change in quality of life from baseline to the end of treatment as assessed by Euro-QoL (EQ5D) questionnaire

Sample Size Calculation {#Sec6}
-----------------------

The study will be conducted as a single-blind, randomized, controlled, hypothesis-generating pilot study. Originally, a systematic statistical case number calculation was performed. The estimated reduction in HbA1c due to iron substitution in type 1 diabetes patients reported in the published literature is − 2.3% \[[@CR5]\]. Calculating with a power of 80%, an alpha of 0.05, and an expected HbA1c difference due to intravenous iron substitution in the present study of 0.7% ± 1.4%, a total of *n* = 126 participants (63 per treatment arm) must be included in the CLEVER trial in order to reach statistical significance. Assuming a 20% expected dropout rate, this sample size would need to be increased to 152 participants, i.e., 76 per treatment group. However, if the dropout rate is only 10%, 70 patients per treatment arm will be sufficient to reach statistical significance. An interim analysis is planned in order to re-evaluate the validity of the hypothesis for the HbA1c difference between the two treatment arms after 64 patients (32 patients per arm) have completed the study. This interim analysis will follow the three zones method described by Mehta and Pocock \[[@CR12]\] using the Lan--DeMets procedure and an O'Brien--Fleming spending function. The final number of participants to be included will be adjusted during the study depending on the dropout rate and results from the interim analysis.

Statistical Methods {#Sec7}
-------------------

Continuous variables will be checked for normality using the Kolmogorov--Smirnov test, and non-normally distributed variables will be log-transformed before analysis. If no normal distribution is obtained, the Mann--Whitney *U* test will be used instead of a *t* test. A summary of baseline data (demographic, anamnestic data, and laboratory parameters) will be provided. The compilation will involve a comparison of mean values, indicating the corresponding standard deviations, as well as*t* tests between the treatment arms. For nominal variables, the frequency will be counted and tested using the chi-square test to check for significant differences between treatment groups.

Changes in primary and secondary parameters between baseline and the end of the study will be tested using a paired *t* test or a Wilcoxon rank sum test for each treatment arm and using an independent *t* test for the last visit between treatment arms. A boxplot or confidence interval plot will be presented. If the baseline values of HbA1c are significantly different between the treatment groups, an analysis of covariance (ANCOVA) for HbA1c at the last visit will be needed. A linear model will be searched for using stepwise regression (forward and backward selection) with all independent variables at the beginning of the selection.

All nominal and categorical variables will be summarized descriptively with the following parameters: number of observations and absolute and relative frequencies based on the number of observations. Continuous and ordinal variables will be summarized by means of number of observations, arithmetic mean, standard deviation, median, p5, p25, p75, and p95 percentiles, and the minimum and maximum. Correlations will be calculated using Pearson correlation coefficients.

The statistical analysis of primary and secondary endpoints will be done on the per-protocol set, which includes all participants who are randomized and treated according to the protocol. Safety parameters will be listed for all participants who received at least one dose of study medication.

Discussion {#Sec8}
==========

Roughly one-third of the general population is affected by ID, which is one of the most common nutritional deficiencies worldwide \[[@CR13]\]. ID designates a reduction in storage iron (as shown by reduced serum ferritin and confirmed by decreased bone marrow iron staining) as well as decreased utilizable iron (represented by reduced transferrin saturation values), which indicates the amount of immediately available iron. Several chronic disorders such as rheumatic disease, metabolic syndrome, coronary artery disease, and chronic liver disease are confounded by alterations in iron homeostasis \[[@CR14]--[@CR17]\], and correcting ID may impact morbidity, mortality, and quality of life in these patients. Iron deficiency anemia (IDA) is a global public health burden and appears to be more common in people with diabetes than in the nondiabetic population. IDA negatively affects glycemic control. Thus, correcting IDA can be expected to improve diabetes control and prevent disease-related complications \[[@CR18]\].

The bidirectional relationship between iron metabolism and glucose homeostasis is increasingly being recognized. A relative iron excess appears to affect metabolic processes such as insulin action and secretion. Consequently, ensuring balanced body iron stores may be a promising therapeutic target for people suffering from T2DM as well as for those at risk of developing T2DM \[[@CR2]\]. In a population of 883 subjects with no known history of diabetes, Shimodaira et al. \[[@CR19]\] demonstrated that serum iron levels were not associated with insulin resistance or β-cell function. However, it was speculated that insulin secretion was negatively affected by higher hemoglobin levels.

HbA1c, the major form of glycated hemoglobin, was incorporated into a monitoring program for individuals with diabetes in 1976, and is now the gold standard for glycemic control. In healthy people, HbA1c reaches a steady state at 3.0%--6.5% (9--48 mmol/mol) of the overall body hemoglobin, while the HbA1c fraction is abnormally elevated in patients with chronic hyperglycemia and is positively correlated with glycemic control. However, certain conditions such as genetic variants that alter HbA1c through nonglycemic pathways may affect its validity as marker for glycemic control \[[@CR20]\]. Furthermore, the reliability of HbA1c as a biomarker for the diagnosis of diabetes and for monitoring treatment in patients with diabetes suffering from imbalanced iron homeostasis is being questioned, as iron depletion spuriously increases HbA1c values---there is no corresponding change in blood glucose \[[@CR10]\]. Rajagopal \[[@CR4]\] as well as Silva \[[@CR21]\] and coworkers demonstrated a statistically significant difference in HbA1c values between cases of mild, moderate, and severe IDA, even in nondiabetic individuals. On the other hand, a significant drop in HbA1c with iron substitution therapy has been observed in various populations, including people with no history of diabetes and people with type 1 diabetes (see Table [4](#Tab4){ref-type="table"}). Notably, the only study that investigated the effect of iron supplementation in a population with T2DM included patients who additionally suffered from chronic kidney disease. As such, this study was also able to demonstrate that intravenous iron caused a significant decrease in HbA1c values without any change in glycemic control in patients who primarily had T2DM and ID \[[@CR22]\].Table 4Studies demonstrating a decrease in HbA1c after iron substitution therapy (HbA1c values are given as mean ± SD or \[95% confidence interval\])ReferencePopulation*n*HbA1c before treatmentHbA1c after treatmentDifference in mean HbA1cTreatmentDavis 1983 \[[@CR30]\]68-year-old woman with IDA and DM110.7% (without IDA)\
15.4%\
(with IDA)11%4.4%Not disclosedTarim 1999 \[[@CR5]\]Patients with type 1 DM and ID1110.6% ± 2.6%8.3% ± 2.6%2.3% (*P* \< 0.05)Oral 6 mg/kg/day for 3 monthsTarim 1999 \[[@CR5]\]Nondiabetic patients with ID117.7% ± 1.3%6.4% ± 1.2%1.3% (*P* \< 0.05)Oral 6 mg/kg/day for 3 monthsEl-Agouza 2002 \[[@CR7]\]Students with IDA516.15% ± 0.62%5.25% ± 0.45%0.9% (*P* \< 0.001)Oral ferrous sulphate 325 mg/day for 20 weeksCoban 2004 \[[@CR6]\]Nondiabetic patients with IDA507.4% ± 0.8%6.2% ± 0.6%1.2% (*P* \< 0.001)Oral 100 mg/day for 3 monthsNg 2010 \[[@CR22]\]Patients with type 2 DM and chronic kidney disease157.40% \[6.60--8.19\]6.96% \[6.27--7.25\]0.4% (*P* \< 0.001)Single dose of low molecular weight iron dextran as IV infusion

In the literature, several hypotheses for the increase in HbA1c under iron-depleted conditions have been discussed. Brooks et al. \[[@CR23]\] proposed that the quaternary structure of the hemoglobin molecule is altered in ID, which may result in more rapid glycosylation of the β chain. Other scientists have argued that conditions affecting erythrocyte turnover may also influence HbA1c concentrations, and have suggested that the rise in HbA1c may be a result of reduced cell production in IDA, leading to an extended lifespan of circulating erythrocytes \[[@CR24]\]. Studies by El-Agouza et al. \[[@CR7]\] and Coban et al. \[[@CR6]\] demonstrated elevated levels of HbA1c in IDA patients which significantly decreased after iron substitution therapy. They postulated that under conditions of IDA, the decreased hemoglobin concentration would result in an increased glycated fraction if the serum glucose remained constant.

Interestingly, a series of other studies investigating the effect of IDA on HbA1c draw a contradictory picture, as they revealed a decreased HbA1c at baseline and a subsequent rise with iron supplementation, or no difference between IDA and nonanemic populations \[[@CR25]--[@CR27]\].

Although this topic has been addressed by many groups within the last decade, and a couple of hypotheses have been proposed, there is still no sufficiently proven explanation that supports any of these hypotheses in particular, and so further studies are warranted to shed more light on the relationship between ID and HbA1c. However, there is a general consensus that abnormalities in erythrocyte indices are a considerable confounder in the analysis of HbA1c, and there is currently insufficient data to guide physicians in everyday clinical practice. Therefore, English et al. \[[@CR28]\] elaborated a couple of recommendations to consider in addition to the published guidance. For the time being, implementing these rules would prevent the misdiagnosis of diabetes in people with ID who are in the threshold range of HbA1c, as well as the overtreatment of well-adjusted people with diabetes who develop ID and would, in the worst case scenario, end up with a high risk of hypoglycemia.

The investigator-initiated CLEVER trial is designed to evaluate if people with T2DM profit from intravenous iron therapy with FCM. Recently, HbA1c \> 6.5% (48 mmol/mol) has been introduced as the cutoff limit for newly diagnosed diabetes. This level of HbA1c control is recommended by national and international guidelines. Thus, falsely high measured levels of HbA1c due to ID would lead to overtreatment, with potentially high risks of hypoglycemia and weight gain in known diabetics who receive insulin treatment. This underscores that valid HbA1c values are particularly important in people under strict glucose control. Correcting ID is presumed to improve glucose status in these patients and may additionally have a positive clinical impact on vascular function in patients with T2DM on oral antidiabetic combination therapy. Many people with diabetes already have an impaired quality of life and ID constitutes an additional burden. A reduced hemoglobin level also identifies diabetics who are at an increased risk of adverse outcomes, independent of the presence or severity of nephropathy.

In the present study, reconstitution or at least an improvement in iron homeostasis will be achieved by intravenous infusion of FCM, which has greater bioavailability and compliance and was demonstrated to be more effective and (due to its lack of gastrointestinal intolerance) better tolerated than oral iron \[[@CR29]\]. Thus, the study will also provide important data about the pharmacodynamics of ferric carboxymaltose and address the question of whether data attained after intravenous iron substitution therapy are comparable to those obtained after oral dosing, as well as checking the timeframe required to achieve a clinically measurable improvement. A series of parameters for the characterization of easily available iron and iron stores will be evaluated along with parameters of glycemic status. HbA1c will serve as the primary endpoint, in line with many clinical studies that investigate the effects of new medications as potential novel treatments for diabetes. However, other markers for glycemic control, such as fasting blood glucose, fructosamine, and administered insulin dosage, will be determined along with HbA1c concentrations to prove the reliability of this indicator. Furthermore, treatment-emergent adverse events and the quality of life of each study participant will be monitored. Finally, the clinical results obtained from the CLEVER trial will provide further scientific insight into the relationship between iron and metabolic status as well as its clinical relevance.

Conclusion {#Sec9}
==========

The aim of the CLEVER trial is to further investigate the link between ID, intravenous iron substitution, and HbA1c (the most clinically relevant biomarker used for diagnosing and treating type 2 diabetes as a widespread disease). It is hypothesized that intravenous substitution with FCM significantly reduces HbA1c in people with ID and T2DM, thereby improving metabolic status and quality of life. Conversely, this would mean that people suffering from ID might be misdiagnosed with diabetes. Moreover, if a diagnosis of T2DM has already been made and therapeutic control is achieved by relying on HbA1c values, patients suffering from ID are potentially overtreated, leading to a significant risk of hypoglycemic episodes. Consequently, the role of HbA1c as a biomarker for diagnosing and treating diabetes would likely need to be reconsidered, and changes in/restrictions on the interpretation of HbA1c values in ID patients would have to be implemented in national and international diabetes guidelines.

The results of the CLEVER trial will presumably support the use of intravenous FCM in clinical practice, especially in people suffering from diabetes and ID. As HbA1c evaluation is a cornerstone of diabetes management, it is also necessary from a drug safety point of view to critically demonstrate the validity of HbA1c as the most important clinical biomarker for monitoring diabetes therapy by performing a randomized, controlled study of a population suffering from T2DM during drug therapy with FCM, which has been shown to significantly influence and bias this parameter.
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